ESR1 and breast cancer: Using CRISPR/Cas9 technology, Ma et al. discovered that LATS deletion inhibits ESR1 transcription through the LATS-YAP-TEAD-VGLL3 axis (Hippo-YAP pathway) in Luminal BC PDOs lacking the Hippo pathway kinase LATS.